newsfilter
← Latest News
Business Wire·

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027 Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB Spruce Biosciences, Inc.